At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARVN Arvinas Holding Company LLC
Pre-Market Trading 12-23 06:20:30 EST
18.48
+0.65
+3.65%
盘前17.71
-0.77-4.17%
05:25 EST
High18.70
Low17.53
Vol1.76M
Open17.62
D1 Closing17.83
Amplitude6.56%
Mkt Cap1.27B
Tradable Cap1.06B
Total Shares68.71M
T/O31.92M
T/O Rate3.08%
Tradable Shares57.18M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Barclays Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
BRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium
Arvinas and Pfizer Announce Initial Phase 1B Data From the Tactive-U Sub-Study of Vepdegestrant in Combination With Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.